Healthcare-Associated Infections Portfolio

A comprehensive suite of solutions for the screening & infection management of HAIs and MDROs


Setting higher standards in the fight against HAIs

The efficiency and versatility offered by the BD Max™ System and the Healthcare-Associated Infections (HAIs) portfolio provides a comprehensive suite of solutions on a single, fully automated platform, enabling the laboratory to provide rapid, accurate results which can positively impact patient management.



Each year, hundreds of millions of patients worldwide are affected by HAIs, or infections acquired in healthcare settings, leading to2,3

Significant mortality
Human and economic burden
Prolonged hospital stays
Long-term disability
Increased antimicrobial resistance

Early and accurate detection of HAIs combined with appropriate infection control interventions and patient treatment can:

Support antimicrobial stewardship initiatives
Prevent transmission
Improve patient management

4 million patients in Europe per year acquire an HAI1, at a cost of an estimated €7 billion to healthcare providers.2

Compounding the impact of HAIs are infections due to bacteria resistant to antimicrobials (AMR), many resistant to multiple antimicrobials (MDROs). Therefore, AMR is a major concern in relation to HAIs.


Meet the BD MAX™ Portfolio of HAI assays

The BD MAX™ Portfolio of HAI assays enables your laboratory to:

React quickly to outbreaks with up to 120 samples in a 8-hours shift

Increase lab efficiency by decreasing hands-on time for laboratory technicians versus traditional methods

Limit the risk of potential errors and maintain chain of custody including sample transfers and manual manipulations

Flexible testing for HAIs with the capability to run multiple assay types at the same time* * BD assays are run & rack compatible – Only MDR-TB is not run and rack compatible / Vaginal Panel, GBS and open systems’ assays are only run compatible.

Detection of Gram-negative or Gram-positive pathogens



Active surveillance of methicillin-resistant Staphylococcus aureus (MRSA) with Extended Detection Technology including mecA and mecC resistance


Surveillance and differentiation of Staphylococcus aureus and MRSA


BD MAX™ Cdiff

Detection of toxigenic Clostridioides difficile through the identification of toxin B gene (tcdB)

VIASURE VanR Real Time PCR Detection Kit for BD MAX™

Active surveillance of vancomycin-resistant enterococci through the detection of vanA and vanB genes

BD MAX™ CPO assay

Screening for carbapenemase-producing organism (CPO) through the identification of the five most common carbapenemase genes:

OXA-48 (OXA-48 and OXA-48 like)

BD MAX™ Cdiff

Screening for extended-spectrum beta-lactamase (ESBL) producing pathogenic enterobacteria, can be run in parallel with BD MAX™ Check-Points CPO to detect ESBLs and carbapenemases simultaneously:

CTX-M-1 group
CTX-M-2 group
CTX-M-9 group

The BD MAX™ System is a single platform
providing you with the versatility of running BD and partner developed assays,
as well as 3rd party and laboratory developed tests.

Contact us to discuss how we can support your HAI screening needs


CPO, Carbapenemase-Producing Organism; CTX, cefotaxime-beta lactamases; ESBL, Extended-Spectrum Beta-Lactamase; HAI, Healthcare-Associated Infections; IMP, imipenemase; KPC, Klebsiella pneumoniae carbapenemase; MDRO, Multidrug-Resistant Organism; MRSA, Methicillin-Resistant Staphylococcus aureus; NDM, New Delhi metallo-β-lactamase; OXA, oxacillinase; SHV, sulphydryl variable; tcdB, toxin B gene; VIM, Verona integron-encoded metallo-β-lactamase

BD, the BD Logo, BD MAX are trademarks of Becton, Dickinson and Company or its affiliates. © 2023 BD. All rights reserved.

The BD MAX System, BD MAX Enteric Bacterial & Extended Enteric Bacterial Panels, BD MAX Enteric Viral Panel & BD MAX Enteric Viral Panel-NR, BD MAX Enteric Parasite Panel, BD MAX Vaginal Panel, BD MAX Check-Points CPO, BD MAX MRSA XT & BD MAX StaphSR, BD MAX Cdiff, BD MAX MDR-TB, BD SARS-CoV-2 Reagents for BD MAX System, BD SARS-CoV-2/Flu for BD MAX System, VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX System, VIASURE SARS-CoV-2, Flu (A+B) & RSV Real Time PCR Detection Kit for BD MAX System, VIASURE Flu A, Flu B & RSV Real Time PCR Detection Kit for BD MAX System, VIASURE Vancomycin Resistance Real Time PCR Detection Kit for BD MAX System are in vitro diagnostic medical devices bearing a CE mark.

The BD CTGC2 and BD CTGCTV2 assays for BD MAX System are in vitro diagnostic medical devices bearing a CE mark and are CE certified by BSI Group The Netherlands B.V. (Notified Body Number = 2797).

  1. European Centre for Disease Prevention and Control. ECDC Programme on antimicrobial resistance and healthcare-associated infections. Available at: Accessed February 2021.
  2. World Health Organization. Health care-associated infections fact sheet. Available at: Accessed February 2020.
  3. World Health Organization. 2016. Health care without avoidable infections. Available at:;jsessionid=C477D74DC9AF05C3BEA0474CF2C8B601?sequence=1. Accessed February 2020.